Urothelium endoglin antibodies have been shown to recognize small‐caliber vessels that are associated with angiogenesis in bladder cancer that can help identify high‐risk patients who could benefit from antiangiogenic therapeutic regimens.39 This evidence concerns the gene ENG and urinary bladder carcinoma.